“We are deeply disappointed that CMS passed on addressing the issue of copay assistance for prescription drugs and requiring insurers and pharmacy benefit managers (PBMs) to count assistance towards patient out-of-pocket cost-sharing and deductibles,” commented Carl Schmid, executive director of the HIV+Hepatitis Policy Institute.
Washington DC… Today, the Trump administration rushed out the partial release of the rules that govern how private health plans must operate in 2022 and in doing so…
Washington DC… In a victory for patients’ ability to afford prescription drugs, the Trump administration has delayed for two years implementation of a provision included in a proposed…
Washington DC… In a review of health insurance plans being offered on federal and state exchanges in 2021, the HIV+Hepatitis Policy Institute is finding that many plans will not be…
Washington DC… House appropriators are proposing minimal increases for addressing the HIV epidemic in the United States by providing $90 million in increased funding in their FY2021…